Benefit-risk assessment conceptual framework for exposure to biologics during pregnancy

被引：0

作者：

Bozzi, Laura ^{[1
]}

Jacobson, Melanie H. ^{[2
]}

Yost, Emily ^{[3
]}

Cafone, Joseph ^{[1
]}

Sheahan, Anna ^{[4
]}

Levitan, Bennett S. ^{[1
]}

Nelson, Robert M. ^{[5
]}

机构：

[1] Janssen Pharmaceut, Beerse, Belgium

[2] Janssen Res & Dev, Raritan, NJ USA

[3] Janssen, Beerse, Belgium

[4] Janssen Res & Dev LLC, Raritan, NJ USA

[5] Johnson & Johnson, New Brunswick, NJ USA

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

1124

引用

页码：529 / 529

页数：1

共 50 条

[21] Benefit-Risk Assessment of Nonprescription Diclofenac
Brass, Eric P.
Swanson, Jessica
Weisman, Steven M.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 464 - 465
[22] An interdisciplinary conceptual study of Artificial Intelligence (AI) for helping benefit-risk assessment practices
Chassang, Gauthier
Thomsen, Mogens
Rumeau, Pierre
Sedes, Florence
Delfin, Alejandra
AI COMMUNICATIONS, 2021, 34 (02) : 121 - 146
[23] A new framework to address challenges in quantitative benefit-risk assessment for medical products
Fu, Bo
Li, Xuefeng
Scott, John
He, Weili
CONTEMPORARY CLINICAL TRIALS, 2020, 95
[24] Incorporation of a Benefit-Risk Assessment Framework Into the Clinical Overview of Marketing Authorization Applications
Wolka, Anne
Warner, Margaret
Bullok, Kristin
Wang, JuAn
Radawski, Christine
Noel, Rebecca
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (01) : 130 - 134
[25] Incorporation of a Benefit-Risk Assessment Framework Into the Clinical Overview of Marketing Authorization Applications
Anne Wolka
Margaret Warner
Kristin Bullok
JuAn Wang
Christine Radawski
Rebecca Noel
Therapeutic Innovation & Regulatory Science, 2016, 50 : 130 - 134
[26] Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives
Leong, James
McAuslane, Neil
Walker, Stuart
Salek, Sam
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 (09) : 1004 - 1012
[27] Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature
Kurzinger, Marie-Laure
Douarin, Ludivine
Uzun, Ievgeniia
El-Haddad, Chantal
Hurst, William
Juhaeri, Juhaeri
Tcherny-Lessenot, Stephanie
THERAPEUTIC ADVANCES IN DRUG SAFETY, 2020, 11
[28] Benefit-Risk Assessment of Orlistat in the Treatment of Obesity
Priya Sumithran
Joseph Proietto
Drug Safety, 2014, 37 : 597 - 608
[29] A Benefit-Risk Assessment of Caffeine as an Analgesic Adjuvant
Wei-Ya Zhang
Drug Safety, 2001, 24 : 1127 - 1142
[30] Benefit-Risk Assessment of Raloxifene in Postmenopausal Osteoporosis
Ann Cranney
Jonathan D. Adachi
Drug Safety, 2005, 28 : 721 - 730

← 1 2 3 4 5 →